CYP2W1 is a member of the cytochrome P450 enzyme family, which plays a role in metabolizing exogenous and endogenous compounds, including drugs and carcinogens. Unlike other CYP enzymes, CYP2W1 exhibits limited expression in normal tissues but is frequently overexpressed in certain cancers, such as colorectal, gastric, and hepatocellular carcinomas. This tumor-selective expression has drawn interest in its potential as a diagnostic biomarker or therapeutic target. CYP2W1 antibodies are tools developed to detect and study the enzyme’s expression, localization, and functional roles in cancer biology. These antibodies, often monoclonal or polyclonal, enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to analyze CYP2W1 levels in tumor samples or cell lines. Research suggests CYP2W1 may activate prodrugs or carcinogens within tumors, influencing tumor progression or drug resistance. However, its precise biological role remains unclear, partly due to variability in expression patterns across studies. Challenges include ensuring antibody specificity, as cross-reactivity with other CYP isoforms can occur. Validations using knockout models or mass spectrometry are critical. Therapeutic strategies exploring CYP2W1. such as antibody-drug conjugates or enzyme-activated prodrugs, are under preclinical investigation. Despite unresolved questions, CYP2W1 antibodies remain vital for elucidating its oncogenic mechanisms and advancing targeted cancer therapies.